Australija - anglų - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - pioglitazone hydrochloride -

Australija - anglų - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - pioglitazone hydrochloride -

Australija - anglų - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - pioglitazone hydrochloride -

Australija - anglų - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - pioglitazone hydrochloride -

Australija - anglų - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - pioglitazone hydrochloride -

Australija - anglų - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pioglitazone hydrochloride, quantity: 16.53 mg (equivalent: pioglitazone, qty 15 mg) - tablet, uncoated - excipient ingredients: polysorbate 80; hypromellose; colloidal anhydrous silica; lactose monohydrate; croscarmellose sodium; magnesium stearate - vexazone is indicated for the treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea, in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pioglitazone hydrochloride, quantity: 33.06 mg (equivalent: pioglitazone, qty 30 mg) - tablet, uncoated - excipient ingredients: croscarmellose sodium; hypromellose; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; polysorbate 80 - vexazone is indicated for the treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea, in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pioglitazone hydrochloride, quantity: 49.59 mg (equivalent: pioglitazone, qty 45 mg) - tablet, uncoated - excipient ingredients: hypromellose; colloidal anhydrous silica; croscarmellose sodium; lactose monohydrate; polysorbate 80; magnesium stearate - vexazone is indicated for the treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea, in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - pioglitazone hydrochloride, quantity: 49.59 mg (equivalent: pioglitazone, qty 45 mg) - tablet, uncoated - excipient ingredients: hyprolose; carmellose calcium; lactose monohydrate; magnesium stearate - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea; in combination with insulin. as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - pioglitazone hydrochloride, quantity: 33.06 mg (equivalent: pioglitazone, qty 30 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; carmellose calcium; magnesium stearate; hyprolose - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea; in combination with insulin. as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.